Shares of OPKO Health OPK fell 6.4% in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were up 144.44% year over year to $0.04, which were in line with the estimate of $0.04.
Revenue of $428,100,000 higher by 87.11% from the same period last year, which beat the estimate of $374,360,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Oct 29, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/qfhg6q72
Recent Stock Performance
Company's 52-week high was at $6.47
Company's 52-week low was at $1.12
Price action over last quarter: down 23.40%
Company Description
Opko Health is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a specialty active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
